Lexaria raises ~$5.9M via warrant exercise at $12.92/share; issues new warrants

Lexaria Bioscience Corp.

453,969 existing warrants exercised at reduced $12.92/share, gross proceeds ~$5.9M before fees.
New Series A warrants (5-yr, $12.67) and Series B warrants (18-mo, $12.67) issued for 453,969 shares each.
H.C. Wainwright acts as placement agent; fee 7% of gross proceeds plus 15,889 agent warrants at $16.15.
CEO cites $2.6M Australian Tax Office rebate received; proceeds to fund 2027 operations and R&D.
Closing expected Sept 9, 2026; resale registration statement to be filed within 30 days.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.